{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:51:32Z","timestamp":1770987092414,"version":"3.50.1"},"reference-count":8,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000350","name":"Core","doi-asserted-by":"publisher","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}],"id":[{"id":"10.13039\/501100000350","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.lungcan.2015.10.025","type":"journal-article","created":{"date-parts":[[2015,10,30]],"date-time":"2015-10-30T17:17:43Z","timestamp":1446225463000},"page":"617-619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib"],"prefix":"10.1016","volume":"90","clinical-trial-number":[{"clinical-trial-number":"nct00855894","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01000025","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02369484","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02465060","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6661-8733","authenticated-orcid":false,"given":"Bob T.","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"O\u2019Toole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie E.","family":"Chaft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria E.","family":"Arcila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark G.","family":"Kris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7008","key":"10.1016\/j.lungcan.2015.10.025_bib0005","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/431525b","article-title":"Lung cancer: intragenic ERBB2 kinase mutations in tumours","volume":"431","author":"Stephens","year":"2004","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.lungcan.2015.10.025_bib0010","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2012.45.6095","article-title":"Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives","volume":"31","author":"Mazieres","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2015.10.025_bib0015","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/annonc\/mdv186","article-title":"Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors","volume":"26","author":"Kris","year":"2015","journal-title":"Ann. Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2015.10.025_bib0020","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-12-0912","article-title":"Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas","volume":"18","author":"Arcila","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2015.10.025_bib0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2012.01.008","article-title":"Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2\/neu","volume":"76","author":"De Greve","year":"2012","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2015.10.025_bib0030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.lungcan.2015.01.013","article-title":"Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma","volume":"88","author":"De Greve","year":"2015","journal-title":"Lung Cancer"},{"issue":"16","key":"10.1016\/j.lungcan.2015.10.025_bib0035","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.ejca.2015.07.041","article-title":"A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours","volume":"51","author":"Suder","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2015.10.025_bib0040","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/JTO.0000000000000492","article-title":"Distinct epidemiology and clinical consequence of classic versus rare EGFR mutations in lung adenocarcinoma","volume":"10","author":"Lohinai","year":"2015","journal-title":"J. Thorac. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500215300933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500215300933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T01:23:43Z","timestamp":1537233823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500215300933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0169500215300933"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2015.10.025","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2015.10.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}